Skip to Main Content

Author Details

Yaiza N????ez-??lvarez
Institut d'Investigacio Biomedica Sant Pau (IIB SANT PAU)
2014
17
10
PMIDPaper TitleJournal TitlePublished Year
36986589T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.Pharmaceutics2023
36986589T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.Pharmaceutics2023
34847435A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.Biomaterials2022
35421785A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice.Biomed Pharmacother2022
33891374HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes.FEBS J2022
34847435A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.Biomaterials2022
35172149Histone marks regulate the epithelial-to-mesenchymal transition via alternative splicing.Cell Rep2022
35057088Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.Pharmaceutics2022
35421785A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice.Biomed Pharmacother2022
33891374HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes.FEBS J2022
35057088Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.Pharmaceutics2022
35172149Histone marks regulate the epithelial-to-mesenchymal transition via alternative splicing.Cell Rep2022
32563202HDAC11 is a novel regulator of fatty acid oxidative metabolism in skeletal muscle.FEBS J2021
34004204Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.J Control Release2021
33716502Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells.Int J Nanomedicine2021
32602219Loss of HDAC11 accelerates skeletal muscle regeneration in mice.FEBS J2021
32563202HDAC11 is a novel regulator of fatty acid oxidative metabolism in skeletal muscle.FEBS J2021
33716502Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells.Int J Nanomedicine2021
34004204Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.J Control Release2021
32602219Loss of HDAC11 accelerates skeletal muscle regeneration in mice.FEBS J2021
30262812Adipose tissue mitochondrial dysfunction in human obesity is linked to a specific DNA methylation signature in adipose-derived stem cells.Int J Obes (Lond)2019
30262812Adipose tissue mitochondrial dysfunction in human obesity is linked to a specific DNA methylation signature in adipose-derived stem cells.Int J Obes (Lond)2019
28518147Survivin, a key player in cancer progression, increases in obesity and protects adipose tissue stem cells from apoptosis.Cell Death Dis2017
28518147Survivin, a key player in cancer progression, increases in obesity and protects adipose tissue stem cells from apoptosis.Cell Death Dis2017
28262839Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.Sci Rep2017
28262839Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.Sci Rep2017
27416614DNA methylation dynamics in cellular commitment and differentiation.Brief Funct Genomics2016
27416614DNA methylation dynamics in cellular commitment and differentiation.Brief Funct Genomics2016
24838345Genetic and epigenetic determinants of low dysferlin expression in monocytes.Hum Mutat2014
25030697Lineage of origin in rhabdomyosarcoma informs pharmacological response.Genes Dev2014
25313138Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth.Oncotarget2014
24838345Genetic and epigenetic determinants of low dysferlin expression in monocytes.Hum Mutat2014
25030697Lineage of origin in rhabdomyosarcoma informs pharmacological response.Genes Dev2014
25313138Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth.Oncotarget2014
  • 1 - 34 of 34

Recommended Authors

Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2015
Number of shared co-authors 0
Weill Cornell Medical College.
Career Start Year 2013
Number of shared co-authors 1
Guangzhou University
Career Start Year 2013
Number of shared co-authors 0
USC Libraries Bioinformatic Services of the University of Southern California
Career Start Year 2012
Number of shared co-authors 0
Shanghai Pulmonary Hospital, Tongji University School of Medicine
Career Start Year 2010
Number of shared co-authors 0
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 0
Nottingham Trent University
Career Start Year 2010
Number of shared co-authors 0
Texas Children's Cancer Center
Career Start Year 2010
Number of shared co-authors 0
Guangzhou University
Career Start Year 2009
Number of shared co-authors 0
City of Hope National Medical Center
Career Start Year 2009
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 5
Shanghai General Hospital, Shanghai Jiaotong University
Career Start Year 2007
Number of shared co-authors 0
Institute of Biomedical Science and Children's Hospital, Fudan University
Career Start Year 2006
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2005
Number of shared co-authors 1
Oregon Health & Science University
Career Start Year 2005
Number of shared co-authors 0
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Career Start Year 2003
Number of shared co-authors 0
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 0
St. Anna Children's Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 0
Ludwig Institute for Cancer Research, University of California San Diego
Career Start Year 2002
Number of shared co-authors 0
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2001
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Chalmers University of Technology
Career Start Year 2000
Number of shared co-authors 2
Chengdu Medical College
Career Start Year 1999
Number of shared co-authors 0
Uniformed Services University of the Health Sciences
Career Start Year 1997
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
Amsterdam University Medical Center
Career Start Year 1989
Number of shared co-authors 0

Collaborators

Germans Trias i Pujol Research Institute
Co-authored papers 6
Swiss Tropical and Public Health Institute
Co-authored papers 2
MGH Pathology and Harvard Medical School
Co-authored papers 1
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine
Co-authored papers 1
Institute for Frontier Medical Sciences, Kyoto University
Co-authored papers 1
University Medical Center Freiburg, University of Freiburg
Co-authored papers 1
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Co-authored papers 1
University of Texas Health Science Center at San Antonio
Co-authored papers 1
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Stanford University School of Medicine
Co-authored papers 1
Joslin Diabetes Center
Co-authored papers 1
Olivia Newton-John Cancer Research Institute
Co-authored papers 1
University of California san francisco
Co-authored papers 1
University of Texas Health Science Center
Co-authored papers 1
Oregon Health & Science University
Co-authored papers 1
University of Texas Health Science Center
Co-authored papers 1
Kaohsiung Medical University
Co-authored papers 1
Oregon Health and Science University, 3710 SW US Veterans Hospital Rd
Co-authored papers 1
Co-authored papers 1
University of Texas Health San Antonio
Co-authored papers 1
University of Virginia Department of Pathology
Co-authored papers 1
Oregon Health & Science University
Co-authored papers 1
Co-authored papers 1
Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)/CIBERONC
Co-authored papers 1
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
Co-authored papers 1
Zhujiang Hospital, Southern Medical University
Co-authored papers 1
Science Research Laboratories (SRL) 1.
Co-authored papers 1
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic
Co-authored papers 1
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1